Amivantamab with FOLFIRI for second-line colorectal cancer
Part of Cancer, Digestive system clinical trials.
This study tests a new combination of an investigational drug (amivantamab) with two chemotherapies (irinotecan and fluorouracil, known as FOLFIRI) for people whose colorectal cancer has progressed after prior treatment. If you qualify, this might offer another treatment option to help slow the cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 19 years of age or older.
- Your colorectal cancer must have spread (advanced) and cannot be removed by surgery.
- Your tumor must not have changes (mutations) in the KRAS, NRAS, or BRAF genes, and must not have too much HER2 protein.
- You must have already received one treatment that targets EGFR (like cetuximab) along with chemotherapy containing oxaliplatin.
- You must not have received chemotherapy with irinotecan before.
- You must be able to care for yourself (ECOG performance status of 0 or 1) and have adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding amivantamab to standard FOLFIRI chemotherapy for people with certain types of colorectal cancer that have already been treated once. It aims to see if this combination works better than another common treatment (cetuximab or bevacizumab plus FOLFIRI).
This Phase 1/2 study tests amivantamab alone or combined with standard chemotherapy to treat advanced or metastatic colon or rectal cancer. You may be able to join if your tumor has the right genetic profile (typically “wild-type” for certain genes and no HER2 amplification) and your cancer has measurable or biopsy-able lesions.
This trial compares a new combination (amivantamab plus chemotherapy) with the standard treatment (cetuximab plus chemotherapy) as the first therapy for people with left-sided colorectal cancer that has spread. The goal is to see which approach works better when the tumor has no mutations in the KRAS, NRAS, or BRAF genes.
This Phase 2 study tests amivantamab (an antibody medicine) in people with advanced or metastatic non-small cell lung cancer that has specific EGFR gene changes. It may help shrink tumors or control cancer when standard curative treatments aren’t possible.
This trial tests a new combination of two targeted drugs (amivantamab and olomorasib) for people with advanced lung cancer that has a specific KRAS G12C mutation. It's for those whose cancer has grown despite prior chemotherapy and immunotherapy.
This trial tests a new combination of drugs (IB-FOLFIRI) for people with metastatic colorectal cancer that has a specific gene change called BRAF V600E. It is for those whose cancer has grown after at least one prior treatment and who have not had irinotecan stop working.
Hear when a new RAS/BRAF Wild-type Advanced Colorectal Cancer Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.